Efficacy and Related Factors of Ultrasound-guided Lauromacrogol Injection in Treating Symptomatic Hepatic Cysts with a Diameter of <10 cm - A Retrospective Study

Q: What was the main aim of the study?

The study aimed to retrospectively analyze the curative effect and influencing factors of lauromacrogol in treating symptomatic hepatic cysts with a diameter <10 cm.

Q: How were symptoms and treatment response evaluated?

Symptoms were assessed using the Polycystic Liver Disease Questionnaire (PLD-Q) and a 5-point Likert scale. Cyst response was measured by ultrasound-derived volume reduction rate (VRR), with success at 12 months based on both symptom improvement and VRR thresholds.

Q: Which factor was identified as independently associated with treatment failure?

Septa formation after cyst sclerosis was identified as an independent factor related to ineffective treatment.

Sep 30, 2026

Upload by Ophelia

Aims: Retrospectively evaluate the curative effect and influencing factors of lauromacrogol for symptomatic hepatic cysts with a maximum diameter under 10 cm. Methods: Fifty-one patients underwent ultrasound-guided puncture and catheter drainage followed by lauromacrogol sclerotherapy. Symptoms were assessed using the PLD-Q at baseline and 12 months, analyzed with a 5-point Likert scale, while cyst volume reduction rate (VRR) was calculated by ultrasound. Treatment success at 12 months required both symptom improvement and VRR criteria. Results: Effective and ineffective rates were 96.1% and 3.9%. Logistic regression linked larger initial cyst metrics and interval septa formation after sclerosis to VRR outcomes, with septa formation as an independent predictor of failure. Conclusion: Lauromacrogol is effective; septa formation after sclerosis predicts ineffective treatment.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages8

Reading Time20 min

AccessFree to download

Abstract

Aims

Methods

Results

Conclusion

Introduction

[1573-4056/25](1573-4056/25 Send Orders for Reprints to reprints@benthamscience.net)[ Send Orders for Reprints to](1573-4056/25 Send Orders for Reprints to reprints@benthamscience.net)[ ](1573-4056/25 Send Orders for Reprints to reprints@benthamscience.net)[reprints@benthamscience.net](1573-4056/25 Send Orders for Reprints to reprints@benthamscience.net) 1 Current Medical Imaging Content list available at: [https://benthamscience.com/journals/cmir](https://benthamscience.com/journals/cmir) RESEARCH ARTICLE Efficacy and Related Factors of Ultrasound-guided Lauromacrogol Injection in Treating Symptomatic Hepatic Cysts with a Diameter of <10 cm: A Retrospective Study Qingyin Fu1, Bin Hu1, Jixian Lin2, Qiping Liu1, Tonghui Yang1 and Qiong Chen3,* 1Department of Ultrasound, Minhang Hospital, Fudan University, Shanghai, China 2Department of Neurology, Minhang Hospital, Fudan University, Shanghai, China 3Department of Radiology, Dahua Hospital, Xuhui District, Shanghai, China Abstract: Aims: This study aimed to retrospectively analyze the curative effect and influencing factors of lauromacrogol in the treatment of symptomatic hepatic cysts of <10 cm. Methods: In this study, a total of 51 patients with symptomatic hepatic cysts (maximum diameter ranging from 5 cm to 10 cm) were included. Polycystic Liver Disease Questionnaire (PLD-Q) was used to evaluate the symptoms of patients prior to treatment. The patients were followed up at 1, 3, 6, and 12 months after treatment. At the 12-month follow-up, patients were asked to fill out the PLD-Q to assess their symptoms. The improvement rate of patients' symptoms was evaluated using a 5-point Likert scale (worse, 1; slight difference, 2; roughly the same, 3; good, and 4; better, 5. Volume reduction rate (VRR) was calculated by measuring the volume of the cyst cavity via ultrasound. Treatment success at the 12-month follow-up was determined using two criteria: symptom improvement and changes in cyst volume. Symptom improvement was assessed using a Likert Scale, with a score greater than 3 points indicating significant improvement. Additionally, a volume reduction rate (VRR) of 50% or more in cyst size (VRR ≥ 50%) was considered an effective treatment outcome. The relationship between the clinical factors and the ultrasonographic manifestations of hepatic cysts, including the initial maximum diameter of the cyst (measured using ultrasound before operation), the initial volume of the cyst, and the formation of septa after sclerosis of the cyst, was analyzed. Results: All patients completed at least 12 months of follow-up. After a 12-month follow-up, the effective and ineffective rates were 96.1%(49/51) and 3.9%(2/51), respectively. The logistic regression univariate analysis showed significant differences in the initial cyst volume (p = 0.001), the initial maximum diameter of the cyst (p = 0.005), and the interval formation after cyst sclerosis (p = <0.001) between VRR ≥ 50% and VRR < 50% . Logistic regression analysis demonstrated that septa formation after cyst sclerosis was an independent factor related to treatment failure, with an odds ratio of 3.246 (95% confidence interval, 0.784–4.148) . Conclusion: Lauromacrogol is an effective method for hepatic cyst treatment. Septa formation after cyst sclerosis is an independent factor related to ineffective treatment. Keywords: Hepatic cyst, Lauromacrogol, Ultrasound-guided puncture, Likert scale, Sclerotherapy, Logistic regression analysis. | Article History | Received: September 09, 2024 | Revised: March 21, 2025 | Accepted: April 03, 2025 | | --- | --- | --- | --- | 1. INTRODUCTION A hepatic cyst is a benign liver lesion that is commonly encountered in clinical practice and is generally attributed to congenital causes [1, 2] . Hepatic cysts are generally asymptomatic, and most of them are isolated cystic lesions found incidentally. When the size of a hepatic cyst increases, it induces discomfort in the r

FAQs

What was the main aim of the study?

The study aimed to retrospectively analyze the curative effect and influencing factors of lauromacrogol in treating symptomatic hepatic cysts with a diameter <10 cm.

How were symptoms and treatment response evaluated?

Symptoms were assessed using the Polycystic Liver Disease Questionnaire (PLD-Q) and a 5-point Likert scale. Cyst response was measured by ultrasound-derived volume reduction rate (VRR), with success at 12 months based on both symptom improvement and VRR thresholds.

Which factor was identified as independently associated with treatment failure?

Septa formation after cyst sclerosis was identified as an independent factor related to ineffective treatment.

Sep 30, 2026

Upload by Ophelia